Clinical efficacy and safety of combined estradiol valerate and dienogest: A new no-bleed treatment

Climacteric

Volumn 6, Issue SUPPL. 2, 2003, Pages 24-32

  Von Schoultz, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse events; Carbohydrate metabolism; Dienogest; Endometrial proliferation; Estradiol valerate; Hemostasis; Lipids; No bleed treatment

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; LIPID; PLACENTA PROTEIN 14;

ABDOMINAL PAIN; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HEADACHE; HEMOSTASIS; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MASTALGIA; MATHEMATICAL COMPUTING; MENOPAUSAL SYNDROME; MIGRAINE; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; THRUSH; ULTRASOUND; UTERUS BLEEDING;

CLINICAL TRIALS; DRUG COMBINATIONS; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; NANDROLONE; UTERINE HEMORRHAGE;

EID: 0141615902     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Gräser T, Koytchev R, Müller A, Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kilogest® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109-18
2. Gräser T, Römer T, Wiedey KD, Janaud A. Climodien® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332-42
3. Seppala M, Alfthan H, Vartianen E, Stenman UH. The postmenopausal uterus: the effect of hormone replacement therapy on the serum levels of secretory endometrial protein PP14/beta-lactoglobulin homologue. Hum Reprod 1987;2:741-3
4. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regime of estrogen-progestin for treatment of the postmenopausal patient. Am J Obstet Gynecol 1990;162:1534-43
5. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated equine estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92
6. Marslew U, Munk-Nielsen N, Nilas L, Riis BJ, Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas 1994;19:225-37
7. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-16
8. Oettel M, Gräser T, Hoffmann H. Why dienogest as a progestogenic component of postmenopausal nonadrenergic hormone replacement therapy. Drugs Today 2001;37(Suppl G):3-15
9. Gräser T, Müller A, Druckman R, Oettel M. Effects of a combination of 2 mg estradiol valerate and 3 mg dienogest on coagulation, lipid profile and glucose metabolism in postmenopausal women. Drugs Today 2001;37(Suppl G): 87-99